C-Path promotes Cécile Ollivier to Vice President of Global Affairs, expanding leadership in drug development

(Press-News.org) AMSTERDAM and TUCSON, Ariz., January 25, 2024 — Critical Path Institute (C-Path) today announced the promotion of Cécile Ollivier, M.S., from Managing Director, Europe to Vice President of Global Affairs.

“We are thrilled to announce the promotion of Cécile Ollivier to Vice President of Global Affairs,” said C-Path Board member Tomas Salmonson Ph.D., M.S. “Cécile has been an invaluable contributor to our European operations, and her extensive experience in global drug development and regulatory science makes her the ideal choice for this expanded role. Her leadership will be crucial as we continue our mission to accelerate drug development globally.”

Ollivier has been a key figure at C-Path since joining as Managing Director in April 2021. In her new role, she will oversee global strategic initiatives, focusing on enhancing international collaborations and developing innovative approaches to address complex challenges in drug development. Her work will include expanding partnerships and harmonizing regulatory frameworks across multiple regions.

With over 16 years of experience in the healthcare sector, Ollivier has made significant contributions to pediatric and rare disease drug development. Her efforts have been recognized internationally, including as an expert in the International Conference of Harmonization (ICH) and leading the global strategy for pediatric extrapolation.

“Over the past two years, Cécile has orchestrated remarkable growth in C-Path’s European activities, elevated our recognition through insightful contributions at key conferences, and fostered invaluable collaborations,” said C-Path’s CEO Klaus Romero, M.D., M.S., FCP. “Her unwavering commitment to advancing our global initiatives showcases the power of hard work and strategic vision. I look forward to continuing to work closely with Cécile.”

Prior to joining C-Path, Ollivier contributed her expertise at the European Medicines Agency (EMA) and in the medical technology sector, focusing on developing digital endpoints in clinical trials.

“I am honored to take on this new role,” said Ollivier. “The opportunity to further influence global health outcomes and drive innovation in drug development melds perfectly with my passion and experience. I look forward to working with our talented team and our partners around the world to deliver meaningful impact to benefit the lives of individuals and families affected by diseases with unmet needs.” Ollivier’s promotion is effective immediately, and she will be based out of C-Path’s European office in Amsterdam.

 

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

END